In this interview, we had the pleasure of speaking with Robert Fox about biomarker discovery and development in multiple sclerosis, including serum neurofilament light.
Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
Researchers have determined that the blood–brain barrier could be used as a possible biomarker for Alzheimer’s disease; this could potentially result in earlier diagnosis of the disease.
Traumatic brain injury and circulating biomarkers: the CREACTIVE trial, an interview with Guido Bertolini
In this interview, we spoke with Guido Bertolini about the first results from the CREACTIVE trial on circulating biomarkers in traumatic brain injury.
High-acceleration head impacts resulted in elevated serum levels of two biomarkers of traumatic brain injury in American varsity football players displaying no symptoms of concussion.
In this NCTalks podcast, we speak to Jens Kuhle to find out more about his work on monitoring multiple sclerosis using blood neurofilament light protein.
Low levels of vasopressin may be linked to low social ability in monkeys and autism in children, indicating that the hormone could be a biomarker for autism.
AAN 2018: Additional biomarker and vaccine responses announced for ocrelizumab in multiple sclerosis
This week, the American Academy of Neurology (CA, USA) presented findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis patients.
In this editorial from Biomarkers in Medicine, discover how axonal transporter proteins may be utilized as biomarkers for a variety of neurological disorders.
A new study has suggested that monitoring levels of disease-specific microRNAs may be utilized as a potential biomarker for Huntington’s disease, potentially allowing early diagnosis.